CN106902363B - Radioactive composition, single-shot radiosynthesis method and use thereof - Google Patents
Radioactive composition, single-shot radiosynthesis method and use thereof Download PDFInfo
- Publication number
- CN106902363B CN106902363B CN201710106158.0A CN201710106158A CN106902363B CN 106902363 B CN106902363 B CN 106902363B CN 201710106158 A CN201710106158 A CN 201710106158A CN 106902363 B CN106902363 B CN 106902363B
- Authority
- CN
- China
- Prior art keywords
- fdg
- fpa
- nfpglu
- pillar
- sep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 230000002285 radioactive effect Effects 0.000 title claims description 40
- 238000000034 method Methods 0.000 title abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 34
- 230000007062 hydrolysis Effects 0.000 claims abstract description 33
- OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 claims abstract description 29
- 239000002243 precursor Substances 0.000 claims abstract description 25
- 238000003682 fluorination reaction Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000000269 nucleophilic effect Effects 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 5
- 238000011156 evaluation Methods 0.000 claims abstract 4
- 239000003068 molecular probe Substances 0.000 claims description 86
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 238000010189 synthetic method Methods 0.000 claims description 16
- 239000012216 imaging agent Substances 0.000 claims description 13
- 238000012879 PET imaging Methods 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 238000007039 two-step reaction Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 238000012636 positron electron tomography Methods 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 125000005999 2-bromoethyl group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 2
- FBSPHFKZJKWNEC-UHFFFAOYSA-N 2-bromoethyl propanoate Chemical compound CCC(=O)OCCBr FBSPHFKZJKWNEC-UHFFFAOYSA-N 0.000 abstract 1
- 238000003748 differential diagnosis Methods 0.000 abstract 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 36
- 238000003384 imaging method Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 22
- 239000000543 intermediate Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000002699 waste material Substances 0.000 description 9
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 229910052593 corundum Inorganic materials 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 229910001845 yogo sapphire Inorganic materials 0.000 description 8
- 238000011109 contamination Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N tert-butyl alcohol Substances CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- -1 DOPA Amine Chemical class 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- QZZYPHBVOQMBAT-LRAGLOQXSA-N (2s)-2-amino-3-[4-(2-fluoranylethoxy)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC[18F])C=C1 QZZYPHBVOQMBAT-LRAGLOQXSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000005355 lead glass Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000005025 nuclear technology Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to compounds containing multiple radioactivity18F-fluorodeoxyglucose (F-fluorodeoxyglucose)18F‑FDG)、2‑18F-fluoropropionic acid (F-fluoropropionic acid)18F-FPA) and/or (N-2-18F-fluoropropionyl) -L-alpha-glutamic acid (18F-NFPGlu), a single-time radiosynthesis method thereof and application thereof in preparing positron emission tomography medicines. The mixture of mannose triflate and 2-bromoethyl propionate, the mixture of mannose triflate and (N-2-bromopropionyl) -L-alpha-diethyl glutamate or the mixture of mannose triflate, ethyl 2-bromopropionate and (N-2-bromopropionyl) -L-alpha-diethyl glutamate are used as precursors to respectively obtain the medicine containing PET through two steps of nucleophilic fluorination and hydrolysis18F‑FDG+18F‑FPA、18F‑FDG+18F-NFPGlu or18F‑FDG+18F‑FPA+18A composition of F-NFPGlu. The composition of the invention can be used for differential diagnosis and curative effect evaluation of tumors, cardiovascular and cerebrovascular diseases and neuropsychiatric diseases, and can overcome the defect that18Limitations of F-FDG.
Description
[technical field]
The present invention relates to the composition of radioactive compound, its single fraction synthetic method and its in preparation positron emission
Application in tomography drug.The invention particularly relates to contain two kinds of PET drugs18F-FDG+18F-FPA and18F-FDG+18F-
NFPGlu Radioactive composition and contain three kinds of PET drugs18F-FDG+18F-FPA+18F-NFPGlu Radioactive composition, list
Secondary radiation synthetic method and its preparing the application in PET imaging agent.
[background technique]
18F- fluorodeoxyglucose (18It F-FDG is) most widely used in tumour, cardiovascular and cerebrovascular disease and psychoneural
The antidiastole of disease and positron emission fault (PET) imaging agent (drug) of curative effect monitoring, but also will appear some false sun
Property and false negative result.The imaging of different kinds of molecules probe can make up18The deficiency of F-FDG is remarkably improved the sensitivity, special of imaging
Property and accuracy.The imaging of different kinds of molecules probe is repeatedly imaged including divided doses and single-dose images simultaneously[1].Different kinds of molecules
Probe divided doses, which repeatedly image, has been applied to clinical imaging research, shows preferable application prospect.Using O- (2- [18F] fluoro second
Base)-l-tyrosine (18F-FET) with18F-FDG is administered twice imaging twice, helps to identify inflammation and tumour.Using11C- second
Hydrochlorate with18F-FDG is administered twice imaging twice, and the sensitivity and accuracy of hepatoma diagnosis can be improved.Be used in combination (11C-
Methyl)-L-cysteine (MCYS) and18The F-FDG monitoring therapeutic effect on glioma of PET imaging twice, as a result, it has been found that MCYS is obvious
It is better than18F-FDG[2].Since the multiple imaging technique of multiple dosing is cumbersome, researcher is developed using different kinds of molecules probe single
Administration while developing method.Foreign study person is by Parkinson's disease (PD) monkey model one injection99mA kind of Tc-TRODAT-1 (DOPA
Amine transporter imaging agent) and123I-ADAM (serotonin transporter imaging agent) is imaged simultaneously, as a result, it has been found that double show
Track agent can distinguish striatal dopamine transport protein and serotonin transporter, be while assessing PD monkey model intracerebral dopamine
It can system and serotonergic system variation offer process useful[3].Also there is researcher to malignant tumor patient one injection18F-
With18F-FDG mixture carries out a PET/CT scanning, can carry out bone metabolism to tumour patient simultaneously and glucose metabolism images,
Patient care can be improved, reduce review time and number[4].However, different kinds of molecules probe imaging (single-dose simultaneously image and
Divided doses repeatedly image) the multi-stage synthesis different kinds of molecules probe in one day or multiple days is needed, not only time-consuming cost and increase work
Make personnel's exposure dose of radiation, and many centers PET are difficult to complete a variety of PET drug (molecular probe) production use in one day
It is imaged simultaneously in single-dose.In addition, to overcome18The limitation of F-FDG imaging, the imaging of different kinds of molecules probe can make up18F-
Certain deficiencies of FDG.But different kinds of molecules probe divided doses repeatedly image not only troublesome in poeration, time-consuming and increase patient with regard to consultation fee
With, and patient and staff can obtain more radiating irradiation.Though and existing different kinds of molecules probe single-dose images simultaneously
So certain defects that avoidable divided doses repeatedly image, but need while a variety of PET molecular probes being provided, and list can not be solved
The problem of secondary production different kinds of molecules probe not can avoid radiochemistry staff yet and contact less radioactive possibility.
Bibliography:
1. the more target molecule iconographies of Tang Gang China and its progress nuclear technology, 2011,34 (10): 765-771.
2.Deng H,Tang X,Tang G,et al.S-[11C]methyl-L-cysteine, [11C]MCYS:A new
amino acid PET tracer for cancer imagimg.J Nucl Med,2011,52:287–293.
3.Lia IH,Huang WS,Yeh CB,et al.Dual-isotope single-photon emission
computed tomography for dopamine and serotonin transporters in normal and
parkinsonian monkey brains.Nucl Med Biol,2009,36:605–611
4.Iagaru A,Mi ttra E,Yaghoubi SS,et al.Novel strategy for a cocktail18F-fluorideand 18F-FDG PET/CT scan for evaluation of malignancy:Results of
the pilot-phase study.J Nucl Med,2009,50:501–505
[summary of the invention]
For in disease, there are different target spots, and the various single molecule probes with complementation are combined, preparation
Single formulation containing a variety of single molecule probes, i.e. compound molecular probe (Radioactive composition).With compound molecular probe to disease
Molecular imaging is carried out, i.e. compound molecular probe images.The object of the invention is that overcoming18The false positive of F-FDG imaging, false yin
The limitations such as property, provide and are better than18The compound molecular probe (Radioactive composition) containing a variety of PET probes of F-FDG；And it can be complete
Complete solution determine different kinds of molecules probe single production method problem, really radiochemistry personnel are solved from heavy radiation synthetic work
It releases, and can be reduced radioactivity irradiation.
The present invention uses18F-FDG Fully automated synthesis instrument, with 1,3,4,6- tetra--O- acetyl group -2-O- trifyl -
β-D- mannopyranose (abbreviation mannose triflate) and 2- ethyl bromide mixture are precursor, using simple, quick and high
" the two step On-column hydrolysis " of effect can get through nucleophilic fluorination and hydrolysis two-step reaction and small column separating purification and contain two kinds of PET
Drug18F-FDG+18F-FPA compound molecular probe.Equally, with mannose triflate+(N-2- bromo propiono)-L- α-glutamic acid
Diethyl ester admixture is precursor, through nucleophilic fluorination and On-column hydrolysis and small column separating purification, can get and contains two kinds of PET medicines
Object18F-FDG+(N-2-18F- fluorine propiono)-L- α-glutamic acid (18F-NFPGlu) compound molecular probe.With mannose triflate+2-
Ethyl bromide+(N-2- bromo propiono)-L- α-glutamate diethyl ester mixture is precursor, through nucleophilic fluorination and in column water
Solution and small column separating purification can get and contain three kinds of PET drugs18F-FDG+18F-FPA+18F-NFPGlu compound molecular probe
(Radioactive composition).Radioactive composition of the present invention takes water as a solvent according to conventional, and the dosage of Radioactive composition and water is with suitable
Cooperation is PET imaging agent；And be to be substituted into during the preparation process by raw material, it does not add separately.The application of the method solves two
Footwork automated production contains18F marks the problem of a variety of probe compound molecular probes, is Fully automated synthesis compound18F mark molecule
Probe provides universal method, and the synthesis for other compound radioactive molecule probes provides technical foundation.
The present invention relates to contain a variety of probes18F-FDG+18F-FPA+18The single synthesis side of F-NFPGlu compound molecular probe
Method and its single simultaneously image in apply, have broad applicability, compound molecular probe single synthesis and its single can be opened up
Research frontier is imaged simultaneously.Research contents of the present invention has following clear superiority: (1) proposing research and development compound molecule
Probe new strategy solves the key technique problem of more targeted molecular probe preparations.To overcome18F-FDG single molecule probe is aobvious
The limitation of picture, foreign study person have developed a variety of single molecule probe imagings of more targetings and more targeting coupled molecule probe imaging sides
Method.But existing a variety of single molecule probe divided doses repeatedly image needs and repeatedly prepare different unimolecules spies within the not time
Needle；Single-dose images needs simultaneously and repeatedly prepares different single molecule probes in one day using synthesis preparation method by several times；More targets
It is that need to use more complex chemical modification using the single molecule probe imaging technique containing multiple ligand moleculars to the imaging of coupled molecule probe
Method preparation is coupled multiple ligand probes.One pot of single synthesis method and more pots of synthesis preparing methods prepare compound molecular probe, overcome
Divided doses repeatedly image and single-dose images the limitation in terms of preparing molecular probe simultaneously, can be within the same time
The compound molecular probe of the probe containing different kinds of molecules is prepared simultaneously；The imaging of coupled molecule probe is also avoided to need using complicated chemical
Method modifies the drawbacks of multiple ligands prepare coupled molecule probe, and especially overcoming each ligand in coupled molecule probe cannot be certainly
By the limitation for combining its corresponding specific target spot.Existing monomer molecule probe synthesis condition is optimized and improved
Single synthesis is completed to meet the requirements the compound molecular probe of proportion.Compound molecular probe single synthesis method is that research and development are better than18F-
The important development strategy of FDG novel molecular probe also solves the problems, such as more targeted molecular probe synthesis indirectly.(2) containing a variety of
Single molecule probe single dose injection contains a variety of single molecule probe single formulations (single dose), be a kind of innovative more targeting compounds
Molecular probe, and formulate the important development direction of next-generation novel molecular probe.Compound molecular probe preparation is not a variety of
The simple combination of single molecule probe, but a variety of single molecule probes with complementation are prepared through chemical synthesis and by one
Certainty ratio building is combined into compound molecular probe, such as insensitive to hepatoma18F-FDG and the 2- sensitive to hepatoma18F- fluoropropionic acid (18F-FPA), designed, synthesized and building group is combined into compound molecular probe18F-FDG+18F-FPA single dose,
It is substantially better than18F-FDG.And simultaneously although imaging technique is to use various of monomer molecular probe, but this simultaneously to existing single-dose
Instead of compound molecular probe preparation, various of monomer molecular probe preparation are not equivalent to while injecting or taking orally a variety of medicines in matter
Product.Various of monomer molecular probe preparation is several formulations, is equivalent to a variety of drugs；And compound molecular probe preparation (radioactivity group
Close object) it is single dose, it is equivalent to compound drug.(3) imaging of compound molecular probe is a kind of simple, practical and wide spectrum molecular imaging
Method, Transformation Application will bring the deep revolution of molecular image and accurate medicine, open up the molecular imaging new situation.Compound molecule
Probe is (such as18F-FDG+18F-FPA etc.) imaging be expected better than and substituted monomer18F-FDG imaging, and develop and be better than indirectly18F-
The important channel of FDG solves development and is better than18The problem of F-FDG molecular probe is that other compound molecular probes and compound target
Theoretical and experiment basis has been established in the development of drug, opens compound molecular probe imaging frontier.(4) multi-mode compound molecule
The development and Transformation Application of probe will open up the multi-mode compound molecular probe imaging new era, fundamentally solve long-standing problem
The crucial technical problem that the practical challenges of molecular imaging doctor and technical staff, i.e. multi-mode molecular probe image simultaneously,
Obstacle is removed for multi-mode polyfunctional molecule iconography Transformation Application.Multi-mode molecular imaging (such as PET-x computer on line tomography
CT, PET- Magnetic Resonance Imaging MRI, single photon emission computed tomography SPECT-CT etc.) super-sensitive nuclear medicine is shown
As technology with there is high-resolution and combine compared with other image technologies of muting sensitivity, push molecular imaging to enter more
The model molecule iconography new era.But single injects nucleic and magnetic signal group (or other signals group) label simultaneously
Single molecule probe row multi-mode probe molecular imaging simultaneously will be huge challenge even not possible with.If will have different targets
To the specific radiopharmaceutical and on-radiation molecular probe of effect, multi-mode compound molecular probe preparation, Jiu Huiqiao is made
It is wonderful to solve the multi-mode molecular imaging important scientific problems that pendent multi-mode molecular probe images simultaneously always, it realizes multiple
Conjunction molecular probe double mode PET-MRI, SPECT-MRI, PET- ultrasonoscopy, the imaging of PET- optics are possibly realized, and are opened up compound
Molecular probe images the new era.
The invention is realized in this way.
Single molecule probe18F-FDG using mannose triflate as precursor, it is perfluorinated and column hydrolyze two-step method, it is complete in 25min
At Fully automated synthesis (formula 1).Precursor mannose triflate optimum amount is 15-30mg, and fluorination reaction temperature is 80-90 DEG C, reaction
Time 2-5min；It is room temperature reaction 2min in column hydrolysis temperature；Using Sep-Pak Al2O3N Plus pillar, two Sep-Pak
Plus C18 series connection pillar and the small column separating purification of Sep-Pak SCX and neutralized reaction product.
Single molecule probe18F-FPA using 2- ethyl bromide as precursor, it is perfluorinated and column hydrolyze two-step method, at 30 points
Fully automated synthesis (formula 2) is completed in clock.Precursor 2- ethyl bromide optimum amount is 8-20mg, fluorination reaction temperature 110
DEG C, reaction time 10min；It is room temperature, reaction time 2-3min in column hydrolysis temperature；With18F-FDG is the same, using Sep-Pak
Al2O3N Plus pillar, two Sep-Pak plus C18 series connection pillars and the small column separating purification of Sep-Pak SCX and neutralization produce
Object.
Single molecule probe18F-NFPGlu using (N-2- bromo propiono)-L- α-glutamate diethyl ester as precursor, it is perfluorinated and
Two-step method is hydrolyzed in column, completes Fully automated synthesis (formula 3) in 40min.Precursor (N-2- bromo propiono)-L- α-glutamic acid two
Ethyl ester optimum amount is 5-20mg, and fluorination reaction temperature is 110-115 DEG C, reaction time 15min；It is room in column hydrolysis temperature
Temperature, reaction time 5-10min；With18F-FDG is the same, using Sep-Pak Al2O3N Plus pillar, two Sep-Pak plus
C18 series connection pillar and the small column separating purification of Sep-Pak SCX and neutralized reaction product.
The present invention relates to bi-molecular probe PET drugs18F-FDG+18F-FPA compound molecular probe (Radioactive composition)
Single full-automation radiation synthesis.Due to18F-FDG and18Similar method preparation can be used in F-FPA, thus the present invention is with trifluoro
Mannose and 2- ethyl bromide mixture are precursor, and perfluorinated reaction generates 1,3,4,6- tetra--O- acetyl group -2 of intermediate
-18F- β-D- mannopyranose+2-18F- fluoropropionic acid ethyl ester mixture.Add water release it is dilute after, pass through a Sep-Pak Al2O3N
Plus pillar and two Sep-Pak plus C18 series connection pillars, radioactivity intermediate are captured in Sep-Pak plus C18 pillar
In.Add 2M sodium hydroxide solution into pillar, in Sep-Pak plus C18 pillar hydrolysis occurs for intermediate.It is drenched with water
The C18 pillar is washed, after leacheate further passes through the small column separating purification of Sep-Pak SCX and neutralizes, sterilised membrane filter is crossed and obtains18F-
FDG+18F-FPA compound molecular probe.Bi-molecular probe single dose injection (Radioactive composition) synthetic route is as shown in Equation 4.
But18F-FDG+18The single full-automation radiation synthesis of F-FPA compound molecular probe is not simply to apply18F-FDG or18F-FPA synthetic method, and must be in precursor mixture consumption proportion and solvent selection, fluorination reaction temperature and time, Yi Ji
Optimized in terms of column hydrolysis time, could obtain properly putting yield radiochemicsl purity and each component probe put
Penetrating property content respectively accounts for (50.0 ± 10.0) %'s18F-FDG+18F-FPA.Wherein mannose triflate and 2- ethyl bromide quality
When than for 5:8~8:10, perfluorinated and hydrolysis two-step reaction and radioactivity HPLC detection can get contamination and respectively account for
(50.0 ± 10.0) %'s18F-FDG+18F-FPA。18F-FDG+18F-FPA compound molecular probe optimum synthesis condition: precursor mixing
Object dosage mannose triflate (5-8mg) and 2- ethyl bromide (8-10mg), fluorination reaction solvent are acetonitrile or the tertiary fourth of acetonitrile-
Alcohol, (meaning in the present invention " about " is positive and negative five degree to about 100 DEG C of reaction temperature, primarily to balanced reaction.Similarly hereinafter), it reacts
Time is 8-12min, optional 10min；It is room temperature 6-8min in column hydrolysis.
The invention further relates to bi-molecular probe PET drugs18F-FDG+18(the radioactivity combination of F-NFPGlu compound molecular probe
Object) single full-automation radiate synthesis.Due to18F-FDG and18Similar method preparation, thus this hair can be used in F-NFPGlu
It is bright using mannose triflate and (N-2- bromo propiono)-L- α-glutamate diethyl ester mixture as precursor, perfluorinated reaction generation
Tetra--O- acetyl group -2- of intermediate 1,3,4,6-18F- β-D- mannopyranose+(N-2-18F- fluorine propiono)-L- α-glutamic acid two
Ethyl ester mixture.Add water release it is dilute after, pass through a Sep-Pak N Al2O3Plus pillar and two Sep-Pak plus C18 strings
Join pillar, radioactivity intermediate captures in Sep-Pak plus C18 pillar.Add 2M sodium hydroxide solution into pillar, it is intermediate
In Sep-Pak plus C18 pillar hydrolysis occurs for body.The C18 pillar is eluted with water, leacheate further passes through Sep-
After the small column separating purification of Pak SCX and neutralization, crosses sterilised membrane filter and obtain18F-FDG+18F-NFPGlu compound molecular probe.This pair point
Sub- probe compound molecular probe (Radioactive composition) synthetic route is as shown in Equation 5.18F-FDG+18F-NFPGlu compound molecule is visited
Needle synthesis condition with18F-FDG and18F-FPA is different, wherein mannose triflate and (N-2- bromo propiono)-L- α-glutamic acid two
When ethyl ester mass ratio is 5:8~8:15, perfluorinated and hydrolysis two-step reaction and radioactivity HPLC and radio thin layer are chromatographed
(TLC) it detects, can get contamination and respectively account for (50.0 ± 10.0) %'s18F-FDG+18F-NFPGlu.Optimum synthesis condition:
Precursor mixture dosage mannose triflate (5-8mg) and (N-2- bromo propiono)-L- α-glutamate diethyl ester (8-15mg), fluorine
Changing reaction dissolvent is acetonitrile or acetonitrile-tert-butyl alcohol, and about 110 DEG C of reaction temperature, reaction time 12-18min, we are optional
15min；It is room temperature 3-4min in column hydrolysis.It can get in this way18F-FDG and18F-NFPGlu contamination respectively accounts for
(50.0 ± 10.0) %'s18F-FDG+18F-FPA
The invention further relates to three molecular probe PET drugs18F-FDG+18F-FPA+18F-NFPGlu compound molecular probe (is put
Penetrating property composition) single full-automation radiate synthesis.Due to18F-FDG、18F-FPA and18Similar side can be used in F-NFPGlu
Method preparation, thus the present invention is with mannose triflate+2- ethyl bromide+(N-2- bromo propiono)-L- α-glutamic acid diethyl
Ester admixture is precursor, and perfluorinated reaction generates 1,3,4,6- tetra--O- acetyl group -2- of intermediate18F- β-D- mannopyranose+2
-18F- fluoropropionic acid ethyl ester mixture+(N-2-18F- fluorine propiono)-L- α-glutamate diethyl ester mixture.Then it presses18F-FDG
+18The single full-automation radiation of F-FPA compound molecular probe synthesizes similar method, obtains18F-FDG+18F-FPA+18F-
NFPGlu compound molecular probe (Radioactive composition).The three molecular probes compound molecular probe synthetic route is as shown in Equation 6.18F-FDG+18F-FPA+18F-NFPGlu compound molecular probe synthesis condition with18F-FDG、18F-FPA and18F-NFPGlu is different,
Wherein as mannose triflate dosage 5-8mg+2- ethyl bromide 8-10mg+ (N-2- bromo propiono)-in precursor mixture
L- α-glutamate diethyl ester 8-10mg, i.e. mannose triflate, 2- ethyl bromide and (N-2- bromo propiono)-L- α-paddy ammonia
When diethyl phthalate mass ratio is 5:8:8~10:8~10, perfluorinated and hydrolysis two-step reaction and radioactivity HPLC and radioactivity
TLC detection, can get contamination18F-FDG account for (30.0 ± 5.0) %,18F-FPA account for (30.0 ± 5.0) % and18F-
NFPGlu accounts for (40.0 ± 10.0) %'s18F-FDG+18F-FPA+18F-NFPGlu.Optimum synthesis condition: precursor mixture dosage
Mannose triflate (5-8mg)+2- ethyl bromide (8-10mg)+(N-2- bromo propiono)-L- α-glutamate diethyl ester (8-
10mg), fluorination reaction solvent be acetonitrile or acetonitrile-tert-butyl alcohol, about 110 DEG C of reaction temperature, reaction time 12-18min, we
Optional 15min；It is room temperature 8min in column hydrolysis.In this way, can get contamination18F-FDG accounts for (30.0 ± 5.0) %
、18F-FPA account for (30.0 ± 5.0) % and18F-NFPGlu accounts for (40.0 ± 10.0) %'s18F-FDG+18F-FPA+18F-NFPGlu。
18F-FDG+18F-FPA、18F-FDG+18F-NFPGlu and18F-FDG+18F-FPA+18F-NFPGlu Radioactive composition
In colourless or faint yellow clear solution, pH value is between 5.0-8.0.With18F-For starting material,18F-FDG+18F-FPA、18F-
FDG+18F-NFPGlu and18F-FDG+18F-FPA+18Non- putting of the correction for attenuation yield of F-NFPGlu is 20-35%, total Radiochemical purity
Time is about 40min (every kind of compound molecular probe of production, n=5), and specific activity is not less than 3.7 × 1010Bq/mmol.Through radioactivity
HPLC detection,18F-Retention time (Rt) is about 2.5min,18F-FDG+18F-FPA、18F-FDG+18F-NFPGlu and18F-FDG+18F-FPA+18The retention time (Rt) of F-NFPGlu is 3.5-4.0min, with its standard items19F-FDG+19F-FPA、19F-FDG+19F-NFPGlu and19F-FDG+19F-FPA+19F-NFPGlu retention time is consistent, and radiochemical purity is all larger than 95%.For into
One step is distinguished18F-FDG、18F-FPA and18F-NFPGlu, detecting through radioactivity TLC confirms.
The present invention relates to18F-FDG、18F-FPA and18It is mixed that corresponding precursor can also be used in the Radioactive composition of F-NFPGlu
The solid phase fluorination reaction and soda acid liquid phase hydrolysis two-stage process for closing object complete its Fully automated synthesis.Therefore, it is mixed in precursor
It object consumption proportion and solvent selection, fluorination reaction temperature and time and is optimized in terms of column hydrolysis time,
It can also realize18F-FDG、18F-FPA and18F-NFPGlu is bis-/tri- kinds of tracer compound molecular probe single fractions synthesis.As it can be seen that18F-FDG、18F-FPA and18F-NFPGlu is bis-/tri- kinds of tracer compound molecular probe single fraction synthetic methods, it is not limited to liquid
Phase fluorination and in column method for hydrolysis, solid phase fluorination and soda acid liquid phase method for hydrolysis are equally applicable.
[Detailed description of the invention]
Fig. 1 self-control18F-FDG synthesizer schematic diagram.
Fig. 2 is used18The preparation of F-FDG synthesizer18F-FDG+18F-FPA、18F-FDG+18F-NFPGlu or18F-FDG+18F-FPA
+18The Fully automated synthesis process flow chart of F-NFPGlu compound molecular probe；
Fig. 3 compound molecular probe18F-FDG+18The F-FPA single figure of PET imaging simultaneously.Upper figure is coronal-plane PET-CT fusion
Image, the following figure are PET image.
Fig. 4 compound molecular probe18F-FDG+18The F-NFPGlu single figure of PET imaging simultaneously.Upper figure is horizontal shape face PET figure
Picture, the following figure are coronal-plane PET image.
Fig. 5 compound molecular probe18F-FDG+18F-FPA+18PET images coronal-plane figure to F-NFPGlu single simultaneously.
[specific embodiment]
1 dual tracer of embodiment18F-FDG+18The Fully automated synthesis of F-FPA compound molecular probe
Using18F-FDG Fully automated synthesis instrument (Fig. 1) and the preparation of two step On-column hydrolysis contain two kinds of PET drugs18F-FDG+18F-FPA compound molecular probe, is completed under the control of the computer18F-FDG+18F-FPA compound molecular probe automated production,
Synthesis technology process is shown in Fig. 2.Specifically include that (1)18F-F-Trapping.Passed through by cyclotron18O(p,n)18F nuclear reaction is raw
It produces18F-F-, in N2Airborne leukorrhagia, by the pretreatment Sep-Pak l ight QMA anion being placed in radioactive activity measuring meter
Pillar,18F-F-It is trapped in pillar,18O- water is collected in returnable bottle.(2) solvent evaporates.In N2Under effect, in headpin
Containing K2CO3It, will with the acetonitrile solution (1.0-1.5mL) of catalyst K22218F-F-It elutes in confined reaction bottle, heating mixing
For solution to 95 DEG C, evaporated under reduced pressure obtains dry compound [K/K222]+18F-, waste liquid absorbs by the cold-trap that is placed in liquid nitrogen.
(3) fluorination reaction.In N2Under gas effect, precursor mixture mannose triflate (5-8mg) and 2- ethyl bromide in No. 3 bottles
(8-10mg) acetonitrile (or acetonitrile-tert-butyl alcohol) solution (1mL) is pressed into reaction flask, and 5-15min is reacted in 90-105 DEG C of heating.Fluorine
Change after the reaction was completed, is concentrated under reduced pressure, it is cooling.(4) it is trapped in column.In N2Under airflow function, H in No. 2 bottles2O (4.0-8.0mL) adds
Enter in reaction flask, two kinds18F- fluorinated intermediates and H2O mixed liquor is transmitted over a Sep-Pak plus Al2O3Pillar and
In two Sep-Pak plus C18 pillars,18F- fluorinated intermediates mixture is trapped by Sep-Pakplus C18 pillar.With No. 4
H in bottle2O (8.0-15mL) washs pillar, uses N2Drying, the waste collection of the water containing acetonitrile is in waste bottle.(5) in column basic hydrolysis.
NaOH solution (1.0mL) is pressed into reaction flask in kingpin, and is loaded into two Sep Pak plus C18 pillars, hydrolysis
Reaction time is about 2-5min.(6) it neutralizes and isolates and purifies.It is produced in water (4.0-15.0mL) elution C18 pillar in No. 6 bottles
Product, by the way that in Sep-Pak SCX pillar and aqueous slkali, leacheate is in N2Under atmospheric pressure effect, collected after sterilised membrane filter is handled
In sterile product bottle, obtain18F-FDG+18F-FPA compound molecular probe, each component probe radiation content respectively account for (50.0 ±
10.0) %18F-FDG+18F-FPA。
Above-mentioned fluorination reaction can also carry out in solid phase, hydrolysis can also in room temperature NaOH (or KOH) aqueous slkali or
It is completed in heating hydrochloric acid solution.
2 dual tracer of embodiment18F-FDG+18The Fully automated synthesis of F-NFPGlu compound molecular probe
Using18F-FDG Fully automated synthesis instrument (Fig. 1) and the preparation of two step On-column hydrolysis contain two kinds of PET drugs18F-FDG+18F-NFPGlu compound molecular probe, is completed under the control of the computer18F-FDG+18The automatic metaplasia of F-NFPGlu compound molecular probe
It produces, synthesis technology process is shown in Fig. 2.Specifically include that (1)18F-F-Trapping.Passed through by cyclotron18O(p,n)18F core is anti-
It should produce18F-F-, in N2Airborne leukorrhagia, by the pretreatment Sep-Pak l ight QMA yin being placed in radioactive activity measuring meter
Ion pillar,18F-F-It is trapped in pillar,18O- water is collected in returnable bottle.(2) solvent evaporates.In N2Under effect, No. 1
Contain K in bottle2CO3It, will with the acetonitrile solution (1.0-1.5mL) of catalyst K22218F-F-It elutes in confined reaction bottle, heats
For mixed solution to 95 DEG C, evaporated under reduced pressure obtains dry compound [K/K222]+18F-, waste liquid inhaled by the cold-trap that is placed in liquid nitrogen
It receives.(3) fluorination reaction.In N2Under gas effect, precursor mixture mannose triflate (5-8mg) and (N-2- bromo third in No. 3 bottles
Acyl group)-L- α-glutamate diethyl ester (8-15mg) acetonitrile (or acetonitrile-tert-butyl alcohol) solution (1mL) is pressed into reaction flask, 100-
10-15min is reacted in 115 DEG C of heating.After the completion of fluorination reaction, it is concentrated under reduced pressure, it is cooling.(4) it is trapped in column.In N2Airflow function
Under, H in No. 2 bottles2O (4.0-8.0mL) is added in reaction flask, and two kinds18F- fluorinated intermediates and H2O mixed liquor is transmitted over one
A Sep-Pak plus Al2O3In pillar and two Sep-Pak plus C18 pillars,18F- fluorinated intermediates mixture quilt
The trapping of Sep-Pakplus C18 pillar.With H in No. 4 bottles2O (8.0-15mL) washs pillar, uses N2Drying, the waste liquid of the water containing acetonitrile
It collects in waste bottle.(5) in column basic hydrolysis.NaOH solution (1.0mL) is pressed into reaction flask in kingpin, and is loaded into two
In a Sep Pak plus C18 pillar, hydrolysis time is about 5-10min.(6) it neutralizes and isolates and purifies.In No. 6 bottles
Water (4.0-15.0mL) elutes product in C18 pillar, by the way that in Sep-Pak SCX pillar and aqueous slkali, leacheate is in N2Air pressure
Under power effect, collects in sterile product bottle, obtain after sterilised membrane filter is handled18F-FDG+18F-NFPGlu compound molecular probe.
In this way, can get18F-FDG and18F-NFPGlu contamination respectively accounts for (50.0 ± 10.0) %'s18F-FDG+18F-NFPGlu。
Above-mentioned fluorination reaction can also carry out in solid phase, hydrolysis can also in room temperature NaOH (or KOH) aqueous slkali or
It is completed in heating hydrochloric acid solution.
3 three tracer of embodiment18F-FDG+18F-FPA+18The Fully automated synthesis of F-NFPGlu compound molecular probe
Using18F-FDG Fully automated synthesis instrument (Fig. 1) and two step On-column hydrolysis prepare three kinds of PET drugs18F-FDG+18F-
FPA+18F-NFPGlu compound molecular probe, completes its automated production under the control of the computer, and synthesis technology process is shown in figure
2.Specifically include that (1)18F-F-Trapping.Passed through by cyclotron18O(p,n)18F nuclear reaction production18F-F-, in N2Airborne band
Under, by the pretreatment Sep-Pak l ight QMA anion pillar being placed in radioactive activity measuring meter,18F-F-It is trapped in small
In column,18O- water is collected in returnable bottle.(2) solvent evaporates.In N2Under effect, K is contained in headpin2CO3With catalyst K222's
Acetonitrile solution (1.0-1.5mL), will18F-F-It eluting in confined reaction bottle, heating mixed solution is to 95 DEG C, evaporated under reduced pressure,
Obtain dry compound [K/K222]+18F-, waste liquid absorbs by the cold-trap that is placed in liquid nitrogen.(3) fluorination reaction.In N2Gas effect
Under, precursor mixture mannose triflate (5-8mg)+2- ethyl bromide (8-10mg)+(N-2- bromo propionyl in No. 3 bottles
Base)-L- α-glutamate diethyl ester (8-10mg) acetonitrile (or acetonitrile-tert-butyl alcohol) solution (1mL) is pressed into reaction flask, 100-
10-15min is reacted in 115 DEG C of heating.After the completion of fluorination reaction, it is concentrated under reduced pressure, it is cooling.(4) it is trapped in column.In N2Airflow function
Under, H in No. 2 bottles2O (4.0-8.0mL) is added in reaction flask, and three kinds18F- fluorinated intermediates and H2O mixed liquor is transmitted over one
A Sep-Pak plus Al2O3In pillar and two Sep-Pak plus C18 pillars,18F- fluorinated intermediates mixture quilt
The trapping of Sep-Pakplus C18 pillar.With H in No. 4 bottles2O (8.0-20mL) washs pillar, uses N2Drying, the waste liquid of the water containing acetonitrile
It collects in waste bottle.(5) in column basic hydrolysis.NaOH solution (1.0mL) is pressed into reaction flask in kingpin, and is loaded into two
In a Sep Pak plus C18 pillar, hydrolysis time is about 5-10min.(6) it neutralizes and isolates and purifies.In No. 6 bottles
Water (4.0-15.0mL) elutes product in C18 pillar, by the way that in Sep-Pak SCX pillar and aqueous slkali, leacheate is in N2Air pressure
Under power effect, collects in sterile product bottle, obtain after sterilised membrane filter is handled18F-FDG+18F-FPA+18F-NFPGlu compound point
Sub- probe.In this way, can get contamination18F-FDG account for (30.0 ± 5.0) %,18F-FPA account for (30.0 ± 5.0) % and18F-
NFPGlu accounts for (40.0 ± 10.0) %'s18F-FDG+18F-FPA+18F-NFPGlu。
Above-mentioned fluorination reaction can also carry out in solid phase, hydrolysis can room temperature NaOH (or KOH) aqueous slkali or add
It is completed in hot hydrochloric acid solution.
The measurement of 4 product purity of embodiment
It is measured with radioactivity high performance liquid chromatography (HPLC) and thin-layered chromatography (TLC)18F-FDG+18F-FPA、18F-FDG
+18F-NFPGlu and18F-FDG+18F-FPA+18The radiochemical purity of F-NFPGlu compound molecular probe.With the mark for determining structure
Quasi- product19F-FDG+19F-FPA、19F-FDG+19F-NFPGlu and19F-FDG+19F-FPA+19F-NFPGlu, respectively with it is corresponding18F-FDG+18F-FPA、18F-FDG+18F-NFPGlu and18F-FDG+18F-FPA+18F-NFPGlu compound molecular probe is injected together
Into HPLC, or point sample row TLC together, to determine whether its retention time is consistent, and confirmation prepares the authenticity of injection, warp
It measures its radiochemical purity and is all larger than 95%.
HPLC analysis condition: analytical column is ZORBAX Ecl ipse XDB-C18 column, and mobile phase is the acetonitrile of 0.1%TFA
Solution: the aqueous solution of 0.1%TFA, row gradient elution: when 0min, acetonitrile solution/0.1%TFA containing 0.1%TFA is water-soluble
Liquid: 2/98；When being gradually raised to 8min, acetonitrile solution/0.1%TFA aqueous solution of 0.1%TFA: 10/90；It is raised again to 20min
When, acetonitrile solution/0.1%TFA aqueous solution of 0.1%TFA: 80/20.Flow velocity is 1mL/min, ultraviolet detection wavelength 210nm
And 254nm.
For18F-FDG+18F-FPA、18F-FDG+18F-NFPGlu and18F-FDG+18F-FPA+ 18F-NFPGlu compound point
Sub- probe, it is still necessary to TLC methods to be used further to confirm to contain18F-FDG、18F-FPA and18F-NFPGlu.A silica gel plate is taken, is put into
On panel sub-assembling platform behind lead glass, a small amount of probe sample containing different kinds of molecules and its standard items (concentration 0.5mg/ are drawn with capillary
ML), gently put and at one 1mL of distance, it is dried up with hair dryer together on silica gel plate.It is chromatographed, is opened up in chromatography cylinder
Opening agent is acetonitrile: water=95:5 (V/V), is dried up after chromatography with hot-air, carries out thin layer scanning using TLC scanner.After scanning,
TLC plate is uniformly sprayed on iodine staining, or with 2N sulfuric acid, and 110 degree lower to dry 10min dyeing, detection molecules probe sample and standard
The Rf value Rf of product.
Compound molecular probe is detected by radioactivity HPLC and radioactivity TLC18F-FDG+18F-FPA、18F-FDG+18F-
NFPGlu and18F-FDG+18F-FPA+18F-NFPGlu preparation each component monomer probe radiation percentage composition.
The imaging of 5 lotus knurl model small animal position emission tomography (PET) of embodiment
Lotus SPC-A-1 tumor nude mice model, is injected respectively by tail vein by every group 318F-FDG+18F-FPA、18F-FDG+18F-
NFPGlu and18F-FDG+18F-FPA+18F-NFPGlu compound molecular probe (0.2mL, about 3.7-5.5MBq) is to nude mice model body
It is interior.10min anaesthetizes nude mice through intraperitoneal injection 5% chloraldurate (6mL/kg) before imaging, and is placed on fixed plate adhesive tape and fixes, and uses
Heating cushion keeps body temperature.After CT scan, PET data is collected in injection imaging agent different time points, with software (Inevon
Research Workplace 4.1) after row correction for attenuation, iterative approximation image.Sketch the contours of the tissues such as tumour and brain, muscle
Area-of-interest (ROIs) measures the radiocounting and volume of region of interest tissue, calculates per gram of tissue injection dosage percentage
Than (%ID/g), and calculate the radioactive uptakes relative ratios such as tumour/brain, tumour/muscle.Representative single synthesis compound molecule
For lotus knurl model single, image results are shown probe simultaneously, tumor uptake compound molecular probe18F-FDG+18F-FPA is higher than18F-FDG, with18F-FPA similar (Fig. 3)；Tumor uptake compound molecular probe18F-FDG+18F-NFPGlu is higher than18F-FDG, with18F-NFPGlu similar (Fig. 4)；18F-FDG+18F-FPA+18F-NFPGlu has higher intake in tumor tissues, respectively higher than18F-FDG、18F-FPA and18F-NFPGlu (Fig. 5).The model18F-FPA and18F-NFPGlu detection is more sensitive, and18F-FDG
Detect more insensitive, compound molecular probe18F-FDG+18F-FPA and18F-FDG+18F-NFPGlu detection can reach with18F-
FPA and18The same detection effect of F-NFPGlu, and be better than18F-FDG.Equally, it makes18F-FDG it is sensitive and18F-FPA and18F-
NFPGlu insensitive tumor model, compound molecular probe18F-FDG+18F-FPA and18F-FDG+18F-NFPGlu detection can be excellent
In18F-FPA and18F-NFPGlu, and can reach with18F-FDG peer-level.Compound molecular probe, which can detect that, compares monomer molecule
The more lesions of probe.
Claims (9)
1. a kind of Radioactive composition of single fraction synthetic method preparation, wherein the composition of each drug are as follows:18F- fluorodeoxy
Glucose18F-FDG, 2-18F- fluoropropionic acid18F-FPA and/or (N-2-18F- fluorine propiono)-L- α-paddy ammonia
Acid18F-NFPGlu, radioactive dosage percentage range shared by each component are as follows:
1)18F-FDG+18F-FPA,18F-FDG:18F-FPA=60:40~40:60；Or
2)18F-FDG+18F-NFPGlu,18F-FDG:18F-NFPGlu=60:40~40:60；Or
3)18F-FDG+18F-FPA+18F-NFPGlu,18F-FDG:18F-FPA:18F-NFPGlu=25~35:25~35:30
~50, Radioactive composition is soluble in water.
2. the single fraction synthetic method of Radioactive composition described in claim 1, including with mannose triflate and 2- bromo
Ethyl propionate mixture, mannose triflate and (N-2- bromo propiono)-L- α-glutamate diethyl ester mixture or
Before mannose triflate, 2- ethyl bromide and (N-2- bromo propiono)-L- α-glutamate diethyl ester mixture are
Body obtains drug containing PET through nucleophilic fluorination and hydrolysis two-step reaction respectively18F-FDG+18F-FPA,18F-FDG+18F-
NFPGlu or18F-FDG+18F-FPA+18F-NFPGlu Radioactive composition, wherein nucleophilic fluorination reagent is [K/K222]+ 18F。
3. the single fraction synthetic method of Radioactive composition according to claim 2, it is characterised in that described18F-
FDG+18F-FPA compound molecular probe radiates synthetic method, before being with mannose triflate and 2- ethyl bromide mixture
Body, perfluorinated reaction generate 1,3,4,6- tetra--O- acetyl group -2- of intermediate18F- β-D- mannopyranose+2-18F- fluoropropionic acid ethyl ester mixture；Add water release it is dilute after, pass through a Sep-PakAl2O3NPlus pillar and two Sep-
PakplusC18 series connection pillar, radioactivity intermediate capture in Sep-PakplusC18 pillar；
Into pillar, in Sep-PakplusC18 pillar hydrolysis occurs adding sodium hydroxide solution for intermediate；It is eluted with water
The C18 pillar after leacheate further passes through the small column separating purification of Sep-PakSCX and neutralizes, is crossed sterilised membrane filter and is obtained18F-FDG
+18F-FPA Radioactive composition；Wherein mannose triflate and 2- ethyl bromide mass ratio are 5:8~8:10.
4. the single fraction synthetic method of Radioactive composition according to claim 2, it is characterised in that described18F-
FDG+18F-NFPGlu preparation radiates synthetic method, with mannose triflate and (N-2- bromo propiono)-L- α-glutamic acid
Diethyl ester admixture is precursor, and perfluorinated reaction generates 1,3,4,6- tetra--O- acetyl group -2- of intermediate18F- β-D-
Mannopyranose+(N-2-18F- fluorine propiono)-L- α-glutamate diethyl ester mixture；Add water release it is dilute after, pass through one
Sep-PakNAl2O3Plus pillar and two Sep-PakplusC18 series connection pillars, radioactivity intermediate are captured in Sep-
In PakplusC18 pillar；Into pillar, intermediate hydrolyzes adding sodium hydroxide solution in Sep-PakplusC18 pillar
Reaction；The C18 pillar is eluted with water, it is excessively sterile after leacheate further passes through the small column separating purification of Sep-PakSCX and neutralizes
Filter membrane obtains18F-FDG+18F-NFPGlu Radioactive composition；Wherein mannose triflate and (N-2- bromo propiono)-L-
α-glutamate diethyl ester mass ratio is 5:8~8:15.
5. the single fraction synthetic method of Radioactive composition according to claim 2, it is characterised in that described18F-
FDG+18F-FPA+18F-NFPGlu compound molecular probe radiates synthetic method, with mannose triflate, 2- ethyl bromide
(N-2- bromo propiono)-L- α-glutamate diethyl ester mixture is precursor, and perfluorinated reaction generates intermediate 1,3,
4,6- tetra--O- acetyl group -2-18F- β-D- mannopyranose+2-18F- fluoropropionic acid ethyl ester mixture+(N-
2-18F- fluorine propiono)-L- α-glutamate diethyl ester mixture, add water release it is dilute after, pass through a Sep-
PakAl2O3NPlus pillar and two Sep-PakplusC18 series connection pillars, radioactivity intermediate are captured in Sep-
In PakplusC18 pillar；Into pillar, intermediate hydrolyzes adding sodium hydroxide solution in Sep-PakplusC18 pillar
Reaction；The C18 pillar is eluted with water, it is excessively sterile after leacheate further passes through the small column separating purification of Sep-PakSCX and neutralizes
Filter membrane obtains18F-FDG+18F-FPA+18F-NFPGlu Radioactive composition；Wherein mannose triflate, 2- ethyl bromide
(N-2- bromo propiono)-L- α-glutamate diethyl ester mass ratio is 5:8:8~10:8~10.
6. the Radioactive composition of single fraction synthetic method preparation described in claim 1 is preparing answering in PET imaging agent
With.
7. the Radioactive composition of single fraction synthetic method preparation according to claim 6 is in preparation PET imaging agent
Application, it is characterised in that18F-FDG+18F-FPA Radioactive composition is for tumour, cardiovascular and cerebrovascular disease and nerve essence
The antidiastole of refreshing disease and curative effect evaluation PET imaging agent.
8. the Radioactive composition of single fraction synthetic method preparation according to claim 6 is in preparation PET imaging agent
Application, it is characterised in that18F-FDG+18F-NFPGlu Radioactive composition is used for tumour, cardiovascular and cerebrovascular disease and nerve
The antidiastole of mental disease and curative effect evaluation PET imaging agent.
9. the Radioactive composition of single fraction synthetic method preparation according to claim 6 is in preparation PET imaging agent
Application, it is characterised in that18F-FDG+18F-FPA+18F-NFPGlu Radioactive composition is used for tumour, cardiovascular and cerebrovascular disease
And antidiastole and the curative effect evaluation PET imaging agent of neuropsychiatric disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710106158.0A CN106902363B (en) | 2017-02-27 | 2017-02-27 | Radioactive composition, single-shot radiosynthesis method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710106158.0A CN106902363B (en) | 2017-02-27 | 2017-02-27 | Radioactive composition, single-shot radiosynthesis method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106902363A CN106902363A (en) | 2017-06-30 |
| CN106902363B true CN106902363B (en) | 2019-11-12 |
Family
ID=59207901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710106158.0A Active CN106902363B (en) | 2017-02-27 | 2017-02-27 | Radioactive composition, single-shot radiosynthesis method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106902363B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091681B (en) * | 2018-08-09 | 2021-08-03 | 中山大学附属第一医院 | [18F]Trifluoromethyl sulfur-containing amino acid PET developer and preparation method and application thereof |
| CN110483278A (en) * | 2019-08-06 | 2019-11-22 | 唐刚华 | The fluoro- 3- of 2,2- bis-18F- fluoropropionic acid and its synthetic method and application |
| CN114700006B (en) * | 2022-06-07 | 2023-03-24 | 北京先通国际医药科技股份有限公司 | Production equipment of liquid composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1765911A (en) * | 2005-11-18 | 2006-05-03 | 南方医科大学南方医院 | 2- 18The synthesis technique of F-2-DDG |
| CN106344938A (en) * | 2016-09-18 | 2017-01-25 | 中山大学附属第医院 | Targeted imaging agent for detecting glioma as well as preparation method and application thereof |
-
2017
- 2017-02-27 CN CN201710106158.0A patent/CN106902363B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1765911A (en) * | 2005-11-18 | 2006-05-03 | 南方医科大学南方医院 | 2- 18The synthesis technique of F-2-DDG |
| CN106344938A (en) * | 2016-09-18 | 2017-01-25 | 中山大学附属第医院 | Targeted imaging agent for detecting glioma as well as preparation method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| Combined Injection of 18F-Fluorodeoxyglucose and 3′-Deoxy-3′-[18F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical:A Proof-of-Concept Study;Xiao-Feng Li et al;《Translational Oncology》;20131231;第6卷(第6期);第775-783页 * |
| Comparison of three 18F-labeled carboxylic acids with 18F-FDG of the differentiation tumor from inflammation in model mice;Hongliang Wang et al;《BMC Medical Imaging》;20160112;第16卷;第1-8页 * |
| Multiple Target-Specific Molecular Imaging Agents Detect Liver Cancer in a Preclinical Model;S. Ke et al;《Current Molecular Medicine》;20121231;第12卷(第8期);第944-951页 * |
| Radiosynthesis and preliminary biological evaluation of N-(2-[18F]fluoropropionyl)-L-glutamine as a PET tracer for tumor imaging;Caihua Tang et al;《Oncotarget》;20160503;第7卷(第23期);第34100-34111页 * |
| 复方分子探针及其显像;唐刚华;《同位素》;20180228;第31卷(第1期);扉页，第49-56页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106902363A (en) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107501393B (en) | Method and kit for synthesizing 18F-labeled amino acid polypeptide drug | |
| CN106902363B (en) | Radioactive composition, single-shot radiosynthesis method and use thereof | |
| CN106967152B (en) | A kind of compound and the preparation method and application thereof of Value linear label | |
| CN106581700B (en) | A kind of novel polypeptide radiopharmaceutical for targeting HER2 and its preparation method and application | |
| CN113292538A (en) | Compound of targeting tumor-associated fibroblast activation protein, preparation method and application thereof, and tumor developer targeting FAP | |
| CN113583089B (en) | Tumor PD-L1 targeted PET imaging agent, labeling precursor, preparation method and application thereof | |
| CN114736112A (en) | Preparation method and application of PET imaging agent for myocardial metabolism | |
| WO2023246830A1 (en) | Method for preparing liquid composition of compound i and use thereof in myocardial metabolism pet imaging | |
| CN111116595A (en) | Radioactive molecular probe with TSPO as target spot and preparation method and application thereof | |
| Wang et al. | Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[18F] fluoroestradiol ([18F] FES) for human breast cancer imaging | |
| Chakravarty et al. | A simple and robust method for radiochemical separation of no-carrier-added 64Cu produced in a research reactor for radiopharmaceutical preparation | |
| WO2023246829A1 (en) | Liquid composition comprising compound i, preparation method and use | |
| CN107118097A (en) | 2-18F- fluoropropionic acids isomers, its synthetic method and its application | |
| CN113105432B (en) | Carbon-11 (C)11C) Radiopharmaceutical, preparation method and application thereof | |
| CN113024542B (en) | Deuterated tropane derivative and application thereof | |
| Kumari et al. | [99mTc-BBPA]: A possible SPECT agent to understand the role of 18-kDa translocator protein (PBR/TSPO) during neuro-glial interaction | |
| CN110577478A (en) | Positron probe and preparation method and application thereof | |
| CN103330951B (en) | Novel VQ polypeptide radioactive medicine and preparation method thereof | |
| CN106631863B (en) | Radiosynthesis method of DTP (polyethylene terephthalate) developer | |
| Wang et al. | Synthesis of N-(6-[18F] Fluoropyridin-3-yl) glycine as a potential renal PET agent | |
| CN112028914B (en) | A kind of18F-boron trifluoride tyrosine kit and application thereof | |
| CN112250680B (en) | Novel berberine derivative and synthesis method and application thereof | |
| Lakshminarayanan et al. | Improved method for preparing Ni (II) complex of (S)-tyrosine Schiff base and its use in the automated synthesis of O-(2′-[18F] fluoroethyl)-L-tyrosine using solid-phase extraction purification | |
| CN107021998A (en) | A kind of positron radionuclide labeling polypeptide for tumor imaging | |
| CN110483278A (en) | The fluoro- 3- of 2,2- bis-18F- fluoropropionic acid and its synthetic method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230321 Address after: No. 1, Dongxuan Road, Economic and Technological Development Zone, Guangzhou City, Guangdong Province, 510000 (provisional edition) Patentee after: GUANGDONG HUIXUAN MEDICINE TECHNOLOGY CO.,LTD. Address before: 510080, No. two, No. 58, Zhongshan Road, Guangzhou, Guangdong, Yuexiu District Patentee before: The First Affiliated Hospital,Sun Yat-sen University |
|
| TR01 | Transfer of patent right |